Phage therapy for treating drug resistant bacteria in cystic fibrosis patients

Antimicrobial resistance is a rising global threat. When these become ineffective, infections can become difficult or impossible to treat, leading to an increase in the spread and severity of disease.

In a new study, published in Nature Medicine, a team of researchers at the Center for Phage Biology and Therapy at Yale discovered a novel approach that may revolutionize the fight against antimicrobial resistance.

In the study, the research team investigated the use of phage therapy—the use of viruses, or phages, to target and kill bacteria—to help patients with cystic fibrosis, a disease in which antimicrobial resistance is a significant issue. The team pioneered a strategy to select phages that not only kill bacteria that cause infections but also weaken surviving bacteria to become less virulent or less resistant to antibiotics.

Joining me today to discuss phage therapy and their research is Jon Koff, MD, Dr. Koff is an associate professor in Yale School of Medicine’s Section of Pulmonary, Critical Care, and Sleep Medicine and medical director of the Center for Phage Biology and Therapy.

Check out the paper: Phage Therapy May Treat Drug Resistance in Patients With Cystic Fibrosis, Study Finds

Watch the video version at Outbreak News TV